Economic Endpoints in clinical trials

被引：8
作者：
Hlatky, MA
机构：
[1] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
来源：
EPIDEMIOLOGIC REVIEWS | 2002年 / 24卷 / 01期
关键词：
D O I：
10.1093/epirev/24.1.80
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Economic endpoints are increasingly common in randomized clinical trials. As a relatively new addition to the field, methods of measuring and analyzing cost data are still evolving. These developments will be stimulated by the demands of the public for efficient and effective medical care, which will be based on the findings of clinical trials.
引用
收藏
页码：80 / 84
页数：5
相关论文
共 19 条
[1]   Cost-effectiveness of a conservative, ischemia-guided management strategy after non-Q-wave myocardial infarction - Results of a randomized trial [J].
Barnett, PG ;
Chen, S ;
Boden, WE ;
Chow, B ;
Every, NR ;
Lavori, PW ;
Hlatky, MA .
CIRCULATION, 2002, 105 (06) :680-684
[2]   A CLINICIAN GUIDE TO COST-EFFECTIVENESS ANALYSIS [J].
DETSKY, AS ;
NAGLIE, IG .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (02) :147-154
[3]   Methods for analyzing health care utilization and costs [J].
Diehr, P ;
Yanez, D ;
Ash, A ;
Hornbrook, M ;
Lin, DY .
ANNUAL REVIEW OF PUBLIC HEALTH, 1999, 20 :125-144
[4]   Estimating the costs attributable to a disease with application to ovarian cancer [J].
Etzioni, R ;
Urban, N ;
Baker, M .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (01) :95-103
[5]   THE DISTINCTION BETWEEN COST AND CHARGES [J].
FINKLER, SA .
ANNALS OF INTERNAL MEDICINE, 1982, 96 (01) :102-109
[6]  
Gold MR, 1996, COST EFFECTIVENESS H
[7]   Role of economic models in randomized clinical trials [J].
Hlatky, MA .
AMERICAN HEART JOURNAL, 1999, 137 (05) :S41-S46
[8]  
KEELER EB, 1983, MANAGE SCI, V29, P300, DOI 10.1287/mnsc.29.3.300
[9]  
Lord J, 1999, HEALTH ECON, V8, P323, DOI 10.1002/(SICI)1099-1050(199906)8:4<323::AID-HEC431>3.0.CO
[10]  
2-0
12